FibroBiologics Common Stock Forecast - Naive Prediction
| FBLG Stock | 0.38 0.02 5.00% |
FibroBiologics Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of FibroBiologics Common's historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 27th of January 2026, The RSI of FibroBiologics Common's share price is at 55. This usually indicates that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling FibroBiologics Common, making its price go up or down. Momentum 55
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.1) | EPS Estimate Current Year (0.48) | EPS Estimate Next Year (0.41) | Wall Street Target Price 7 | EPS Estimate Current Quarter (0.12) |
Using FibroBiologics Common hype-based prediction, you can estimate the value of FibroBiologics Common Stock from the perspective of FibroBiologics Common response to recently generated media hype and the effects of current headlines on its competitors.
FibroBiologics Relative Strength Index
The Naive Prediction forecasted value of FibroBiologics Common Stock on the next trading day is expected to be 0.38 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 1.49.FibroBiologics Common Hype to Price Pattern
Investor biases related to FibroBiologics Common's public news can be used to forecast risks associated with an investment in FibroBiologics. The trend in average sentiment can be used to explain how an investor holding FibroBiologics can time the market purely based on public headlines and social activities around FibroBiologics Common Stock. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of FibroBiologics Common's market sentiment to its price can help taders to make decisions based on the overall investors consensus about FibroBiologics Common.
The Naive Prediction forecasted value of FibroBiologics Common Stock on the next trading day is expected to be 0.38 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 1.49. FibroBiologics Common after-hype prediction price | USD 0.38 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
FibroBiologics | Build AI portfolio with FibroBiologics Stock |
FibroBiologics Common Additional Predictive Modules
Most predictive techniques to examine FibroBiologics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for FibroBiologics using various technical indicators. When you analyze FibroBiologics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
FibroBiologics Common Cash Forecast
Predicting cash flow or other financial metrics requires analysts to utilize a variety of statistical methods, techniques, and algorithms. These tools help uncover hidden patterns in the FibroBiologics Common's financial statements, enabling forecasts of their impact on future stock prices.
Cash | First Reported 2010-12-31 | Previous Quarter 16.1 M | Current Value 16.9 M | Quarterly Volatility 6.1 M |
FibroBiologics Common Naive Prediction Price Forecast For the 28th of January
Given 90 days horizon, the Naive Prediction forecasted value of FibroBiologics Common Stock on the next trading day is expected to be 0.38 with a mean absolute deviation of 0.02, mean absolute percentage error of 0, and the sum of the absolute errors of 1.49.Please note that although there have been many attempts to predict FibroBiologics Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that FibroBiologics Common's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
FibroBiologics Common Stock Forecast Pattern
| Backtest FibroBiologics Common | FibroBiologics Common Price Prediction | Buy or Sell Advice |
FibroBiologics Common Forecasted Value
In the context of forecasting FibroBiologics Common's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. FibroBiologics Common's downside and upside margins for the forecasting period are 0 and 9.81, respectively. We have considered FibroBiologics Common's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of FibroBiologics Common stock data series using in forecasting. Note that when a statistical model is used to represent FibroBiologics Common stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.0755 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.024 |
| MAPE | Mean absolute percentage error | 0.0785 |
| SAE | Sum of the absolute errors | 1.4868 |
Predictive Modules for FibroBiologics Common
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as FibroBiologics Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.FibroBiologics Common After-Hype Price Density Analysis
As far as predicting the price of FibroBiologics Common at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in FibroBiologics Common or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of FibroBiologics Common, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
FibroBiologics Common Estimiated After-Hype Price Volatility
In the context of predicting FibroBiologics Common's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on FibroBiologics Common's historical news coverage. FibroBiologics Common's after-hype downside and upside margins for the prediction period are 0.02 and 9.78, respectively. We have considered FibroBiologics Common's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
FibroBiologics Common is out of control at this time. Analysis and calculation of next after-hype price of FibroBiologics Common is based on 3 months time horizon.
FibroBiologics Common Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as FibroBiologics Common is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading FibroBiologics Common backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with FibroBiologics Common, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.41 | 9.42 | 0.02 | 0.02 | 26 Events / Month | 8 Events / Month | In about 26 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.38 | 0.38 | 0.00 |
|
FibroBiologics Common Hype Timeline
FibroBiologics Common is currently traded for 0.38. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of 0.02. FibroBiologics is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at 0.41%. %. The volatility of related hype on FibroBiologics Common is about 22975.61%, with the expected price after the next announcement by competition of 0.40. About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.48. FibroBiologics Common had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 26 days. Check out Historical Fundamental Analysis of FibroBiologics Common to cross-verify your projections.FibroBiologics Common Related Hype Analysis
Having access to credible news sources related to FibroBiologics Common's direct competition is more important than ever and may enhance your ability to predict FibroBiologics Common's future price movements. Getting to know how FibroBiologics Common's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how FibroBiologics Common may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DARE | Dare Bioscience | (0.02) | 11 per month | 0.00 | (0.04) | 6.55 | (6.98) | 26.52 | |
| ATHA | Athira Pharma | (0.10) | 4 per month | 3.40 | 0.11 | 7.83 | (6.40) | 70.38 | |
| ADTX | Aditxt Inc | (0.04) | 10 per month | 0.00 | (0.27) | 22.54 | (28.09) | 63.67 | |
| AIMD | Ainos Inc | 0.11 | 6 per month | 0.00 | (0.20) | 6.71 | (9.79) | 28.00 | |
| CTXR | Citius Pharmaceuticals | 0.10 | 10 per month | 0.00 | (0.15) | 10.59 | (10.53) | 38.23 | |
| MBRX | Moleculin Biotech | (0.50) | 9 per month | 0.00 | (0.19) | 9.76 | (11.73) | 41.63 | |
| LPTX | LPTX Old | 0.01 | 9 per month | 6.90 | 0.14 | 25.00 | (9.43) | 65.13 | |
| APLM | Apollomics Class A | 0.63 | 4 per month | 0.00 | (0.04) | 17.08 | (17.51) | 44.38 | |
| ICU | SeaStar Medical Holding | 0.17 | 9 per month | 0.00 | (0.18) | 9.58 | (9.88) | 34.66 | |
| HOTH | Hoth Therapeutics | 0.05 | 26 per month | 0.00 | (0.15) | 4.81 | (6.84) | 14.85 |
Other Forecasting Options for FibroBiologics Common
For every potential investor in FibroBiologics, whether a beginner or expert, FibroBiologics Common's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. FibroBiologics Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in FibroBiologics. Basic forecasting techniques help filter out the noise by identifying FibroBiologics Common's price trends.FibroBiologics Common Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with FibroBiologics Common stock to make a market-neutral strategy. Peer analysis of FibroBiologics Common could also be used in its relative valuation, which is a method of valuing FibroBiologics Common by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
FibroBiologics Common Market Strength Events
Market strength indicators help investors to evaluate how FibroBiologics Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading FibroBiologics Common shares will generate the highest return on investment. By undertsting and applying FibroBiologics Common stock market strength indicators, traders can identify FibroBiologics Common Stock entry and exit signals to maximize returns.
FibroBiologics Common Risk Indicators
The analysis of FibroBiologics Common's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in FibroBiologics Common's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting fibrobiologics stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.95 | |||
| Semi Deviation | 8.27 | |||
| Standard Deviation | 9.09 | |||
| Variance | 82.56 | |||
| Downside Variance | 111.56 | |||
| Semi Variance | 68.37 | |||
| Expected Short fall | (7.83) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for FibroBiologics Common
The number of cover stories for FibroBiologics Common depends on current market conditions and FibroBiologics Common's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that FibroBiologics Common is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about FibroBiologics Common's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
FibroBiologics Common Short Properties
FibroBiologics Common's future price predictability will typically decrease when FibroBiologics Common's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of FibroBiologics Common Stock often depends not only on the future outlook of the potential FibroBiologics Common's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. FibroBiologics Common's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 32.9 M | |
| Cash And Short Term Investments | 14 M |
Check out Historical Fundamental Analysis of FibroBiologics Common to cross-verify your projections. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.